Tune Therapeutics, a Durham biotechnology startup co-founded by a Duke professor, announced the completion of its Series B fundraising round on Jan. 12, in which it raised $175 million to support ...
Regeneron, San Diego-based biotech company Illumina and 17 health systems invested in the $320 million round. Regeneron ...
The LIGHTHOUSE study is a Phase I/II, open-label, dose-escalation and dose-expansion clinical trial evaluating the safety and tolerability of ATSN-201 in male patients ages six and older with a ...
She has held research leadership roles at organizations including Juno Therapeutics, Celgene, and Lyell Immunopharma and is currently the head of research at Tune Therapeutics. She brings strong ...
Her previous roles at Juno Therapeutics, Celgene, and Lyell Immunopharma, and her current position as head of research at Tune Therapeutics, underscore her commitment to pioneering cancer treatments.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results